跳至主要内容
临床试验/NCT03432663
NCT03432663已完成4 期

Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation

Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2008年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
Obtain a continuous sinus rhythm

研究概览

简要总结

Sixty consecutive emergency patients with newly diagnosed Atrial Fibrillation were randomized into two groups. The first received intravenous amiodarone infusions continuously for 24 hours; the second received Amiodarone until sinus rhythms was reached or for up to 72 hours.

The efficacy and safety of administering intravenous infusions of amiodarone for up to 72 hours were investigated and compared to the efficacy and safety of administering a standard 24 hours infusion of amiodarone. Specifically, the use of up to 72 hours infusions was considered as a new strategy to improve rates of conversion to sinus rhythm without altering the safety profile of the drug.

详细描述

An open randomized clinical trial was conducted that included 60 emergency adult patients who were candidates for drug cardioversion after first symptomatic episodes of AF.

The patients were randomized in equal proportions and sequentially placed in one of two treatment groups; no patient knew to which group he or she belonged. The first group received intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 hours was reached. The second group received intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 hours for up to 72 hours.

All patients were continuously monitored using electrocardiograms, and echocardiograms were performed within 24 hours after the randomized trial began. The exact time of each patient's cardioversion was documented. In addition, general laboratory tests, lipid profiles, thyroid profiles and chest X-rays were obtained for all patients.

A sample size of 30 subjects in each group was calculated. A conversion rate of 60% was assumed, according to literature, and an estimated increase to 90% was assumed for the experimental group to find differences with a power of 0.8 and an alpha error of 0.05.

The primary goal was to obtain was a sinus rhythm conversion rate. The secondary goal was to obtain a combined complication rate by noting various complications in the patients, such as phlebitis, symptomatic hypotension that required vasopressors, bradycardia, nausea, vomiting and any organ embolism.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •≥18 years old
  • •Emergency patients
  • •First symptomatic episodes of Atrial Fibrillation

排除标准

  • •Hemodynamic instability,
  • •Previous use of antiarrhythmic drugs
  • •Use of digoxin seven or fewer days prior to the study
  • •Active thyroid disease
  • •Known adverse reactions to amiodarone
  • •Other ventricular arrhythmias
  • •Contraindications for anticoagulation
  • •Acute renal failure
  • •Chronic liver disease
  • •Transaminase levels that were twice the normal levels
  • •Acute pulmonary edema
  • •Uncontrolled hypertension (> 180/110 mmHg)
  • •Unstable angina
  • •Patients who were pregnant and/or breast feeding

研究组 & 干预措施

24h infusion

Experimental

Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached Intravenous amiodarone (1)

干预措施: Intravenous amiodarone(1) (Drug)

72h infusion

Experimental

Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached Intravenous amiodarone (2)

干预措施: Intravenous amiodarone(2) (Drug)

结局指标

主要结局

Obtain a continuous sinus rhythm

时间窗: 72 hours

Monitoring using continuous telemetry.

次要结局

  • Complication rate of continuous amiodarone intravenous infusion(72 hours)

研究者

发起方
Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验